|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Hydrogel Spacer Placement for Prostate Radiotherapy: A Urology Residency Training Experience
|
Zachary Klaassen, MD, MSc
Zachary Klaassen discusses hydrogel spacer placement and resident education, drawing on approximately 250 Barrigel® procedures performed since FDA clearance in 2022.
|
|
|
|
|
|
|
|
|
|
|
|
Rectal Spacing with Hyaluronic Acid Spacer and the Importance of Apical Distance
|
Varun Sundaram, MD
Varun Sundaram discusses Barrigel™ apical spacing technique, drawing on data from the King secondary analysis of the Barrigel™ randomized trial.
|
|
|
|
|
|
|
|
|
|
|
|
NRG-GU005 Trial Compares SBRT and Hypofractionated IMRT for Prostate Cancer
|
|
Rodney Ellis, MD
|
| Rodney Ellis presents NRG-GU005 trial results, revealing nuanced findings in the comparison of SBRT versus moderate hypofractionation for intermediate-risk prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
| Early Results of COMPPARE, a Prospective Comparison of Outcomes with Proton and Photon Radiation in Prostate Cancer
|
| Nancy PMendenhall, MD, FACR, FASTRO
|
| The COMPPARE prospective study of 2,500 men with localized prostate cancer found excellent early outcomes with both IMRT and proton therapy, with nearly identical 3-year freedom from disease progression and no significant differences in patient-reported quality of life or reported toxicity. Rectal spacers substantially reduced GI grade ≥2 toxicity in both groups, while dosimetrically, proton therapy delivered ~50% lower dose to normal tissues, but this did not translate into early clinical toxicity differences.
|
|
|
|
|
|
Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Localised Prostate Cancer (HYPO-RT-PC): 10-Year Outcomes of an Open-Label, Randomised, Phase 3, Non-Inferiority Trial - Beyond the Abstract
|
| Per Nilsson, MD, PhD and Adalsteinn Gunnlaugsson, MD, PhD
|
| The HYPO-RT-PC trial’s 10-year results confirm that ultra-hypofractionated radiotherapy is non-inferior to conventional fractionation for failure-free survival in localized prostate cancer, with no evidence of reduced efficacy and a signal suggesting possible long-term benefit. These mature data support ultra-hypofractionation as an evidence-based standard-of-care option (particularly for intermediate-risk disease), with contemporary techniques expected to further reduce toxicity and future work focusing on risk-adapted intensification and integration with systemic therapies. |
|
|
|
|
|
| Biochemical Control and 2-Year Tolerability Following Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Multicenter Study in Spain - Beyond the Abstract |
| Sigfredo Elias Romero Zoghbi, MD |
| In this Spanish multicenter real-world study of 250 patients with localized prostate cancer treated with SBRT, 2-year biochemical control was 96.4% with radiologic progression in only 2.8%, and late grade ≥2 adverse events were low: 7.6% genitourinary, 1.2% gastrointestinal, and 14.3% sexual, with grade 3 events infrequent Overall survival was 95.6% at 2 years with no prostate cancer-specific mortality, reflecting effective early disease control in a predominantly low- and intermediate-risk cohort. |
|
|
|
|
|
|
|
|
|
|
